• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® TAG® CONFORMABLE THORACIC STENT GRAFT WITH ACTIVE CONTROL SYSTEM; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® TAG® CONFORMABLE THORACIC STENT GRAFT WITH ACTIVE CONTROL SYSTEM; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number TGMR404010
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available (4581)
Date of Event 08/29/2024
Type of Reportable Event Serious Injury
Event or Problem Description
The field sales associate (fsa) reported the following to gore: on (b)(6) 2022, the patient underwent an endovascular procedure to treat an aneurysm utilizing the gore® tag® conformable thoracic stent graft with active control system (ctag) 37 x 15.The physician sealed the aneurysm conservatively, with no endoleak noted.The patient tolerated the procedure.On an unknown date, a type 1a endoleak was identified.On (b)(6) 2023, reintervention (b)(4) was performed to address the type 1a endoleak in zone 3, with proximal extension using a ctag 40 x 10.The patient tolerated the procedure.On an unknown date, proximal thoracic aortic degeneration was observed.On (b)(6) 2024, a second reintervention (b)(4) occurred.Another ctag 37 x 15 was deployed proximally, and a ctag 45 x 20 was used to bridge into the previous ctag 40 x 10 implanted.On (b)(6) 2025, the patient was noted to have a type 1a endoleak and possible type 1b endoleak.On (b)(6) 2025, an emergent endovascular intervention (b)(4) was performed.Another ctag 40 x 10 was deployed proximally with intentional coverage of the left subclavian artery (lsa).Due to access limitations, a distal ctag could not be placed proximal to the celiac artery, and a 24 fr dryseal could not be advanced.The possible type 1b endoleak was not significant enough to intervene on according to the angiogram.No reintervention has occurred on the type 1b endoleak.The patient's thoracic aorta has exhibited progressive proximal degeneration, with each return visit showing growth beyond the existing graft coverage.Captured 5000 - other and 1003 - e due to rapid proximal aortic degeneration.
 
Additional Manufacturer Narrative
H6: code e2402 - captured for thoracic aortic degeneration.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may have not been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Additional Manufacturer Narrative
Added g3/g4, h1/h2, h6.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® TAG® CONFORMABLE THORACIC STENT GRAFT WITH ACTIVE CONTROL SYSTEM
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL PHOENIX 2 B/P
32470 n. north valley parkway
phoenix AZ 85085
Manufacturer Contact
monique nwanze
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key22609590
Report Number3007284313-2025-04140
Device Sequence Number5494129
Product Code MIH
UDI-Device Identifier00733132646838
UDI-Public(01)00733132646838(17)250403
Combination Product (Y/N)N
Initial Reporter StateIL
Initial Reporter CountryUS
PMA/510(K) Number
P040043
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2023
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 09/03/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date04/03/2025
Device Catalogue NumberTGMR404010
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 08/29/2024
Supplement Date Received by Manufacturer09/03/2025
Initial Report FDA Received Date07/25/2025
Supplement Report FDA Received Date09/03/2025
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured04/05/2022
Is the Device Labeled for Single Use? (Y/N) Yes
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age77 YR
Patient SexFemale
-
-